Exelixis’ Cabozantinib Cleared For Kidney Cancer, With Competitive Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to launch within two weeks, priced at a premium to competing drugs in kidney cancer.
You may also be interested in...
Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer
While a combo regimen of Cabometyx and Tecentriq actually showed a lower response rate in lung cancer than a 2020 readout, a doublet of Cabometyx/Keytruda showed promise in head-and-neck cancer.
Exelixis Has Renewed Momentum Heading Into 2021
The approval of Cabometyx in combination with Opdivo as a first-line treatment for RCC will power substantial growth at Exelixis into 2022.
Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown
Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.